Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex/Neostigmine and Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology status (ASA) III~* Ability to give a written informed consent~* Liver transplantation~Exclusion Criteria:~* Any allergy to medications involved in the study~* Any disease involving neuromuscular transmission~* Any therapy with toremifene, flucloxacillin or fusidic acid~* Renal disease with glomerular filtration rate less than 30 ml/min/1.73m2~* Hyperthermia maligna~* Anticonceptional therapy~* Pregnancy~* Core body temperature less than 35°C or skin temperature less than 32°C at the end of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sugammadex (Type: ACTIVE_COMPARATOR): at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
- neostigmine (Type: ACTIVE_COMPARATOR): at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).